UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager - PubMed
3 hours ago
- #immunotherapy
- #T-cell lymphomas
- #bispecific T-cell engagers
- UMG1 is a unique CD43 epitope highly expressed in certain T-cell lymphomas (TCLs) and diffuse large B-cell lymphoma (DLBCL), but absent in most normal tissues.
- A Bispecific T-Cell Engager (UMG1/CD3ε-BTCE) shows potent in vitro and in vivo antitumor activity against UMG1-expressing TCLs.
- IHC analysis revealed high UMG1 expression in 62.3% of TCL samples, including PTCL-NOS and ALK-negative ALCL, with all T-PLL specimens being positive.
- UMG1/CD3ε-BTCE induces robust redirected cytotoxicity against UMG1-expressing TCL cells, enhanced by the HDAC inhibitor SAHA.
- The therapy shows dose-dependent T-cell-mediated cytotoxicity and inflammatory cytokine release, selectively targeting UMG1-expressing cells without affecting non-expressing cells.
- These findings support the development of precision immunotherapy for UMG1-expressing aggressive hematologic malignancies.